No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy
- PMID: 23530103
- DOI: 10.1200/JCO.2012.47.9238
No evidence of survival benefit with addition of gemtuzumab ozogamicin to standard medical research council induction chemotherapy
Comment in
-
Reply to D. Przepiorka et al and M.K. Jensen.J Clin Oncol. 2013 May 1;31(13):1700-1; discussion 1701. doi: 10.1200/JCO.2013.48.6571. J Clin Oncol. 2013. PMID: 23762898 No abstract available.
Comment on
-
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.J Clin Oncol. 2012 Nov 10;30(32):3924-31. doi: 10.1200/JCO.2012.42.2964. Epub 2012 Jul 30. J Clin Oncol. 2012. PMID: 22851554 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
